While cell-free DNA is our business, it’s patients who power our purpose

Matthew Rabinowitz, Ph.D., is co-founder of Natera and currently serves as the executive chairman of its board of directors. From 2005-2009, he served as Natera’s chief executive officer.

Rabinowitz serves as a chairman, director and/or advisor to many companies and nonprofits involved in diagnostics, biotech, artificial intelligence (AI), health services, and nature conservation. Additionally, he manages an early stage technology venture fund focused on biotech, security, and AI.

Companies Rabinowitz has founded have twice received the World Economic Forum Technology Pioneer award and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford, as visiting faculty in Genetics at Harvard, and has received the Scott Helt Award from the Institute of Electrical and Electronic Engineers.

Rabinowitz has authored well over 100 patents and publications respectively, including papers in the top reproductive, transplant, and oncology journals. He led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management, and oversaw the development of a technology that tracks tumor mutations in blood that has reshaped cancer management and received multiple FDA breakthrough designations. He also led the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children, as well as other breakthrough products. In 2024, Rabinowitz was named R&D Leader of the Year by R&D World.

Rabinowitz studied electrical engineering and physics at Stanford University. He received the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed his doctorate in electrical engineering.

Steve Chapman is the chief executive officer of Natera and serves on the company’s board of directors. Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease, the Prospera™ transplant assessment test, the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease, and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.

Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis.

Chapman serves on the board of directors for the American Clinical Laboratories Association (ACLA). In 2024, he was named one of the top healthcare technology CEOs by Healthcare Technology Report, as well as “BioTechnology Innovator of the Year” by BioTech Breakthrough. He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. He has also authored multiple scientific papers.

Chapman holds a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA, where he graduated with honors.

Read More

Alexey Aleshin serves as general manager of oncology and early cancer detection & chief medical officer of Natera. He joined the company in 2017, and has served in many leadership capacities during his tenure including medical director of oncology, vice president of oncology medical affairs, and chief medical officer.

Aleshin has a demonstrated history of working in the biotechnology industry, with a focus on circulating biomarkers and novel clinical trial design and execution. He is an experienced product strategist and cross functional team manager. Earlier in his career, he served as an advisor and consultant for various companies focused on advancing clinical adoption of next generation sequencing technologies.

Aleshin holds his M.D. and an MBA from UCLA. He completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.

Olesya A. Anisimova, CPA, has served in public accounting and industry for over 15 years. During her career, Olesya’s primary focus was on manufacturing and biotechnology industries. Olesya came from Ernst & Young and started at Natera in February 2015 as an Assistant Controller and was subsequently promoted to Senior Director of Finance & Corporate Controller. Olesya’s role had evolved into VP of Finance and Senior VP of Finance throughout her career at Natera. Since January 2022, Olesya has been serving Natera as the Chief Accounting Officer. Since joining the company in early 2015, Olesya has played a crucial role in the company’s success. She successfully filed Natera’s IPO with the accounting and finance team and is responsible for Natera’s annual and quarterly SEC filings. She has managed a broad range of responsibilities including driving improvements in various operations, performing SEC filings, and SOX compliance controls. She was recently leading on the Company’s new ERP Implementation as well. Olesya continues her role as Chief Accounting Officer for Natera, as well as working closely with the CFO and FPA Team on strategic decisions for company operations.

Mike Brophy is Natera’s chief financial officer. He joined the company in 2015, serving as its senior vice president of finance and investor relations. He also previously served as vice president of corporate development and investor relations at Natera.

Prior to joining Natera, Brophy served as a vice president and executive director in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. His military career included leading a multi-agency, ten-person team on a $1.4 billion contract to modernize ten remote satellite tracking stations worldwide.

Brophy holds a bachelor’s degree in economics from the United States Air Force Academy and an MBA from UCLA.

Jerry Diffley joined Natera in August of 2017 as its chief compliance and privacy officer. He is a seasoned laboratory executive with extensive experience in U.S. and international laboratory compliance, privacy, billing, and laboratory operations.

Prior to joining Natera, Diffley worked at Quest Diagnostics in a variety of operational positions, as well as legal compliance. He is certified as a Compliance Professional and has experience with global compliance organizations, global healthcare, GDPR, privacy, and data security. He has developed corporate-wide compliance programs and lobbied for the healthcare industry at all levels of government.

Diffley holds a bachelor’s degree in education from SUNY Plattsburgh and an MBA in healthcare administration from Stony Brook University.

Dr. Eric Evans joined Natera in 2020 as Chief Scientific Officer. Prior to joining Natera, he was co-founder and Chief Scientific Officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women’s health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis. He received his B.S. in Biological Sciences from the University of Delaware and his Ph.D. in Genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.

John Fesko serves as president and chief business officer of Natera. He leads company-wide efforts across multiple functions and programs, including collaborations with payors, government affairs, business development, market development, pharmaceutical services, patient experience, communications, marketing, and international commercial operations and strategy.

Before joining Natera in 2014, Fesko worked at Roche, Novartis Pharma AG, MPM Capital, and InVivoScribe. He has extensive experience in business development, strategic planning, and product management.

Fesko holds a bachelor’s degree in biochemistry and economics from the University of Notre Dame and an MBA from MIT.

Phil Grinnell is the chief sales officer at Natera, where he oversees the strategy and continued growth of the sales organization across the company. In this role, he leads the U.S. sales teams across women’s health, oncology, and organ health, along with sales training and commercial analytics.

During Grinnell’s tenure at Natera, he has held a number of additional leadership positions including senior vice president of sales and senior director of sales operations. He joined the company in 2011 as a regional sales director.

Earlier in his career, Grinnell spent 5 years with Athena Diagnostics where he gained experience in genetic diagnostic testing in both direct sales and sales leadership.

Grinnell holds an MBA from Villanova University and a B.S. from the University of Texas, Austin. He currently serves as president of the Board of Directors for the Kaisermann Jewish Community Center.

Ramesh Hariharan serves as the general manager of Natera’s women’s health business. He joined Natera in 2016 to head marketing and medical education and later transitioned to his current role.

Hariharan’s career spans a range of subspecialties including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. While working at McKinsey, Hariharan served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K. He has tackled a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds.

Hariharan has also held marketing leadership positions in oncology, women’s health, and vaccines at Novartis, Abbott/AbbVie, and Biotheranostics.

Hariharan holds a bachelor’s degree in chemical engineering from IIT Bombay, an MBA from MIT Sloan School of Management, and a doctorate in chemical engineering from Princeton University.

Rishi Kacker serves as Natera’s Chief Technology Officer, bringing 20-years of experience in software, genetics, and health tech entrepreneurship. At Natera he is responsible for leading a team including product, UX, software engineering and IT with the mission to expand access to genetic testing for millions each year through innovations/transformation in the patient and provider experience. Additionally, the team has launched a massive clinico-genomic data and research platform being used to accelerate our knowledge of genetic disease. Prior to Natera, Mr. Kacker was the Chief Technology Officer at Myriad Genetics and co-founder and SVP of Technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise. Mr. Kacker holds a B.S. degree in computer science from Stanford University.

As Senior Vice President of Laboratory Affairs & Quality, and Natera’s corporate CLIA Laboratory Director, Dr. Keen-Kim is responsible for the overall operation and administration of the clinical laboratories, as well as Natera’s Quality culture. Since joining Natera in 2018, Dr. Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations 4-fold, and provides daily quality oversight and risk management in oncology, women’s health, and transplant diagnostics. With expertise in cell-free DNA, Next Generation Sequencing, and automation technologies, Dr. Keen-Kim earned a bachelor’s degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an Adjunct Clinical Professor at Stanford University School of Medicine. She is licensed by California and New York to direct medical laboratories and maintains three HHS-approved board certifications. Dr. Keen-Kim is a mentor and champion for women leaders and is passionate about staff training and development to create growth opportunities for the next generation.

Chitra Kotwaliwale serves as senior vice president of clinical & commercial operations and portfolio management at Natera. She joined the company in 2019 and has held multiple roles across product management and strategy, overseeing product management for the women’s health team, managing overall strategic planning and project management for Engineering/R&D, and coordinating global product strategy.

Prior to joining Natera, Kotwaliwale served as director of product marketing at Agilent Technologies, where she managed the company’s product management team responsible for target enrichment content products for rare diseases and oncology. She previously served as senior product manager of sequencing at Complete Genomics, and prior to that, as a computational biologist at Adaptive Biotechnologies (formerly Squenta, Inc.).

Kotwaliwale holds a bachelor’s degree in biology from the College of Wooster and a doctorate in molecular and cell biology from the University of Washington and the Fred Hutchinson Cancer Center. She completed her postdoctoral fellowships at the University of California, Berkeley, which was funded by prestigious fellowships from the Damon Runyon Cancer Research Foundation and Howard Hughes Medical Institute.

Solomon Moshkevich serves as president of clinical diagnostics at Natera, where he oversees productization, clinical validation, commercialization, and quality across the company.

Since joining Natera in 2011, Moshkevich has built and led multiple teams including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management, and portfolio strategy. He has played a leading role in the development, clinical validation, and commercial success of all of Natera’s cell-free DNA products including Panorama, Prospera, and Signatera.

Most recently, Moshkevich served as general manager of oncology for the company, overseeing a period of tremendous growth and leading the company’s efforts to achieve Medicare coverage for Signatera across multiple cancer types.

Moshkevich began his career as a consultant with Bain & Company before joining the private equity investment team at Parthenon Capital. He graduated from Columbia University summa cum laude with a bachelor’s degree in economics and mathematics, and he holds an MBA from Stanford University. He currently serves on the Board of Directors for the Ronald McDonald House Charities of the Bay Area.

Sheetal Parma serves as senior vice president of medical affairs for women’s health at Natera. She is a board-certified genetic counselor specializing in prenatal diagnosis and screening.

Since joining Natera in 2013, Parmar has held a number of positions including senior director of clinical genetic services and director of medical education.

Before joining the company, she worked for 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory.

Parmar serves on the Board of Directors for the National Society of Genetic Counselors (NSGC). In 2020, she accepted the Leading Women Entrepreneur Force for Change Illuminator award for her leadership and contributions to Natera’s positive impact on the lives of others during the COVID-19 pandemic.

Parmar holds a bachelor’s degree in molecular and cell biology from UC Berkeley and a master’s degree in genetic counseling from the University of Cincinnati, where she was an Albert C. Yates Scholar and Fellow.

Daniel Rabinowitz is secretary and chief legal officer at Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and before that, was a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management, and compliance with US federal and state securities law.

Rabinowitz holds a bachelor’s degree and an LLB degree from the University of the Witwatersrand, South Africa, graduating at the top of his law school class. He holds an LLM degree from New York University School of Law with both Rotary Foundation and Fulbright Scholarships. He studied genetics, biochemistry, and molecular biology at Harvard University Extension School.

John Ryan joined Natera as its chief laboratory officer in 2023. He brings more than 28 years of operations experience, with expertise in diagnostic laboratory operations, laboratory partnerships, supply chain management, kit manufacturing, and customer service.

Ryan most recently served as senior vice president of operations at Myriad Genetics, overseeing neuroscience, women’s health, oncology, and international operations. At Myriad, he also served as vice president of hereditary cancer operations, senior director of customer service, and senior director of operations. Prior to that, he served in the Armed Forces DNA Identification Lab.

Ryan holds a bachelor’s degree in biochemistry and molecular biology from the University of California, Santa Cruz; an executive MBA from the University of Utah David Eccles School of Business; and a doctorate in genetics from Stony Brook University.

Bernie Tobin is responsible for strategy and execution for Natera’s organ health products. Mr. Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co.  He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.